Nuo Yu, Xiankai Chen, Jiao Li, Xiaozheng Kang, Zhen Wang, Ruixiang Zhang, Jianjun Qin, Yong Li, Qingfeng Zheng, Guojie Feng, Lei Deng, Tao Zhang, Wenqing Wang, Wenyang Liu, Jianyang Wang, Qinfu Feng, Jima Lv, Zongmei Zhou, Zefen Xiao, Nan Bi, Yin Li, Xin Wang
BACKGROUND: To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin as the regimen of conversional chemoradiotherapy (cCRT) in locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma (ESCC). METHODS: Patients with locally advanced ESCC (cT3‑4, Nany, M0‑1, M1 was limited to lymph node metastasis in the supraclavicular area) were enrolled. All the patients received the cCRT of nab-paclitaxel plus cisplatin...
August 12, 2024: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]